Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease
Conditions
Paget's Disease of the Vulva
What is the purpose of this trial?
This is a phase II open-label study of the activity and safety of trastuzumab in patients with vulvar Paget's disease with overexpression of HER2 on biopsy.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Genentech
Yale University - Dates:
- August 2011
- Last Updated:
- August 31, 2011
- Study HIC#:
- 1004006704
Clinicaltrials.gov ID: NCT01427244
For more information about this trial, contact:
Lisa Baker, RN, BSN, OCN
203-785-6398
lisa.baker@yale.edu
Thomas J. Rutherford, MD, PhD
203-785-6301
thomas.rutherford@yale.edu
Investigator
Thomas Rutherford, MD, PhD
Principal Investigator
